AIM: The aim of this study is to review long-term oncologic results of local excision (LE) and to investigate the validity and feasibility of LE as a treatment option for distal rectal cancer. MATERIALS AND METHODS: Seventy-six patients who underwent LE for distal rectal adenocarcinoma with curative intent from 1991 to 2000 at Severance Hospital Yonsei University Medical Center, Seoul, Korea were enrolled in this study. RESULTS: Preoperative transrectal ultrasonography revealed 3 cases of uT0, 55 cases of uT1 and 18 cases of uT2. Postoperative pathologic examination revealed 10 cases of pT0 (where no residual cancer cells remained), 11 cases of pTis, 37 cases of pT1, 16 cases of pT2, and 2 cases of pT3. Eleven out of 37 patients with pT1 tumors received adjuvant radiation therapy. Among 16 patients with pT2 tumor, 7 undertook salvage operation and 8 received adjuvant therapy. The median follow-up period was 84.9 months. Local recurrence was observed in six patients. The 5-year local recurrence-free survival rate (LFS) was 89.4% in the pT1 group and 75.0% in the pT2 group (p = 0.012). Among the patients with pT1 cancer, those who received adjuvant radiation therapy demonstrated a 5-year LFS of 100%, compared to those who did not, 76.0% (p = 0.038). CONCLUSION: Our results imply a potential role of LE and adjuvant radiation as an option for the treatment of distal rectal cancer, and that even for pT1 carcinoma, LE alone might not be a valid modality.
AIM: The aim of this study is to review long-term oncologic results of local excision (LE) and to investigate the validity and feasibility of LE as a treatment option for distal rectal cancer. MATERIALS AND METHODS: Seventy-six patients who underwent LE for distal rectal adenocarcinoma with curative intent from 1991 to 2000 at Severance Hospital Yonsei University Medical Center, Seoul, Korea were enrolled in this study. RESULTS: Preoperative transrectal ultrasonography revealed 3 cases of uT0, 55 cases of uT1 and 18 cases of uT2. Postoperative pathologic examination revealed 10 cases of pT0 (where no residual cancer cells remained), 11 cases of pTis, 37 cases of pT1, 16 cases of pT2, and 2 cases of pT3. Eleven out of 37 patients with pT1tumors received adjuvant radiation therapy. Among 16 patients with pT2 tumor, 7 undertook salvage operation and 8 received adjuvant therapy. The median follow-up period was 84.9 months. Local recurrence was observed in six patients. The 5-year local recurrence-free survival rate (LFS) was 89.4% in the pT1 group and 75.0% in the pT2 group (p = 0.012). Among the patients with pT1cancer, those who received adjuvant radiation therapy demonstrated a 5-year LFS of 100%, compared to those who did not, 76.0% (p = 0.038). CONCLUSION: Our results imply a potential role of LE and adjuvant radiation as an option for the treatment of distal rectal cancer, and that even for pT1carcinoma, LE alone might not be a valid modality.
Authors: C J Kim; T J Yeatman; D Coppola; A Trotti; B Williams; J S Barthel; W Dinwoodie; R C Karl; J Marcet Journal: Ann Surg Date: 2001-09 Impact factor: 12.969
Authors: W M Mendenhall; C G Morris; W R Rout; R A Zlotecki; D S Lind; S N Hochwald; S R Schell; E M Copeland Journal: Int J Cancer Date: 2001 Impact factor: 7.396
Authors: Ramesh Rengan; Philip Paty; W Douglas Wong; Jose Guillem; Martin Weiser; Larissa Temple; Leonard Saltz; Bruce D Minsky Journal: J Clin Oncol Date: 2005-08-01 Impact factor: 44.544
Authors: A A F A Veenhof; R H J Kropman; A F Engel; M E Craanen; S Meijer; O W M Meijer; D L van der Peet; M A Cuesta Journal: Int J Colorectal Dis Date: 2006-09-29 Impact factor: 2.796
Authors: R Zinicola; R Nascimbeni; R Cirocchi; G Gagliardi; N Cracco; M Giuffrida; G Pedrazzi; G A Binda Journal: Tech Coloproctol Date: 2021-06-25 Impact factor: 3.781
Authors: W A A Borstlap; P J Tanis; T W A Koedam; C A M Marijnen; C Cunningham; E Dekker; M E van Leerdam; G Meijer; N van Grieken; I D Nagtegaal; C J A Punt; M G W Dijkgraaf; J H De Wilt; G Beets; E J de Graaf; A A W van Geloven; M F Gerhards; H L van Westreenen; A W H van de Ven; P van Duijvendijk; I H J T de Hingh; J W A Leijtens; C Sietses; E J Spillenaar-Bilgen; R J C L M Vuylsteke; C Hoff; J W A Burger; W M U van Grevenstein; A Pronk; R J I Bosker; H Prins; A B Smits; S Bruin; D D Zimmerman; L P S Stassen; M S Dunker; M Westerterp; P P Coene; J Stoot; W A Bemelman; J B Tuynman Journal: BMC Cancer Date: 2016-07-21 Impact factor: 4.430